NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Processa Pharmaceuticals, Inc. (PCSA) Stock Analysis

Processa Pharmaceuticals, Inc. (PCSA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PCSA

$2.06

+$0.01 (+0.49%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PCSA with… →

PCSA Key Statistics

As of Sep 4, 2026
Trading
Open
$2.02
Previous Close
$2.05
Day's Range
2.01–2.08
52-Week Range
1.67–14.25
Volume
12.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.97
Valuation
Market Cap
$5.75M
P/E Ratio
3.17
EPS (ttm)Profit attributable to each share over the last twelve months.
0.65
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$13.56M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.79M
1-Year Return
−51.53%
Dividend and dates
Avg Volume
242.15K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PCSA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−28.47%
2025−86.97%
2024−86.81%
2023−69.55%
2022−77.55%
2021−25.70%
2020−63.36%
2019−28.57%
2018−18.18%
2017+151.43%
2016 (partial year)−24.24%

As of September 4, 2026.

PCSA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$13.56M—
2024$0.00−$11.85M—
2023$0.00−$11.12M—
2022$0.00−$27.42M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$13.99M−$13.56M—
2024$0.00—−$12.05M−$11.85M—
2023$0.00—−$11.46M−$11.12M—
2022$0.00—−$20.26M−$27.42M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PCSA Valuation vs Biotechnology Median

Median of 656 stocks
MetricPCSABiotechnology medianvs median
P/E3.1712.570.3x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Processa Pharmaceuticals, Inc. (PCSA) carries a market capitalisation of $5.75M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12.

The most recent close on file for PCSA is $2.06, dated September 4, 2026. That is +$0.01 (+0.49%) against the previous close. The 52-week range on file runs from $1.67 to $14.25. The latest close sits 23.35% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $13.56M. The reported profit margin is 0%. Trailing earnings per share are 0.65.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 3.17 times earnings. That is 0.3 times the Biotechnology median of 12.57. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −51.53%. Across 10 years the annualized return works out at −56.29%. Beta against the wider market is reported at 0.97. Annualized volatility over the trailing 10 years is 242.7%.

Growth & Income

The record shows no dividend for PCSA.

Across the complete calendar years on file, 2017 returned +151.43% and 2025 returned −86.97%. Of the 9 complete calendar years on file, 1 finished higher. 2026 is still running; the price is −28.47% year to date.

Peer Comparison

Processa Pharmaceuticals, Inc. (PCSA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Processa Pharmaceuticals, Inc. PCSA $5.75M 3.2
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Processa Pharmaceuticals, Inc. trades at a P/E of 3.2.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Visit website →